

UnitedHealthcare Pharmacy
Clinical Pharmacy Programs

Program Number	2024 P 1351-4
Program	Prior Authorization/Notification
Medication	Orladeyo [®] (berotralstat)
P&T Approval Date	3/2021, 3/2022, 3/2023, 3/2024
Effective Date	6/1/2024

1. Background:

Orladeyo is a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older. Orladeyo should not be used for the treatment of acute HAE attacks.¹

2. Coverage Criteria^a:

<p>A. Orladeyo will be approved based on <u>all</u> of the following criteria:</p> <p>1. Diagnosis of hereditary angioedema (HAE)</p> <p style="text-align: center;">-AND-</p> <p>2. <u>Both</u> of the following:</p> <p>a. For prophylaxis against HAE attacks</p> <p style="text-align: center;">-AND-</p> <p>b. Not used in combination with other products indicated for prophylaxis against HAE attacks (e.g., Cinryze, Haegarda, Takhzyro)</p> <p>Authorization will be issued for 12 months.</p> <p>^a State mandates may apply. Any federal regulatory requirements and the member specific benefit plan coverage may also impact coverage criteria. Other policies and utilization management programs may apply.</p>
--

3. Additional Clinical Rules:

- Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by program and/or therapeutic class.
- Supply limits may be in place.

4. References:

1. Orladeyo [package insert]. Durham, NC: BioCryst Pharmaceuticals, Inc.; March 2022.

Program	Prior Authorization/Notification – Orladeyo (berotralstat)
Change Control	
3/2021	New program.
3/2022	Annual review. Aligned combination use language with prophylactic therapies without change to clinical intent.
3/2023	Annual review. Added state mandate and updated reference.
3/2024	Annual review with no changes to clinical criteria.